The Food and Drug Administration granted marketing approval for Zorvolex, an anti-inflammatory drug. The nonsteroidal anti-inflammatory drug is used to treat adult pain. Zorvolex, Iroko officials said, is the first lower-dose NSAID developed with the SoluMatrix fine particle technology approved by the FDA. That technology was developed by iCeutica, a Philadelphia company that has a partnership and licensing deal with Iroko. Read the full story